Here, we showed that LILRB4 rs1048801 was associated with poor AML treatment response after two cycles treatment (either induction chemotherapy or targeted therapy), significantly affecting treatment sensitivity regardless of the type of chemotherapeutic drugs. This evidence concerns the gene LILRB4 and acute myeloid leukemia.